In line with above findings, our results showed that a lower GLP-1 signaling score was related to a better clinical outcome in patients with urothelial carcinoma and non-small cell lung cancer after immunotherapeutic treatment. The gene discussed is GLP1R; the disease is urothelial carcinoma.